CAREER DEVELOPMENT PROGRAM
职业发展计划
基本信息
- 批准号:8282826
- 负责人:
- 金额:$ 15.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至 2013-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcademyAntineoplastic AgentsAreaAwardBasic ScienceBiochemistryBioethicsBiologyCancer BiologyCancer ControlChestClinicalClinical InvestigatorClinical ResearchClinical TrialsCollaborationsDevelopmentDisciplineDiseaseEducationEnvironmentEpidemiologistEpidemiologyEthicsFacultyFinancial SupportFosteringFundingFutureGoalsGrantGroomingHead and Neck CancerHead and Neck SurgeryHead and neck structureIndividualInstitutesInstitutionK-Series Research Career ProgramsLaboratoriesLongitudinal StudiesMalignant NeoplasmsMalignant neoplasm of lungMedical OncologyMentorsMentorshipMethodologyMinorityModelingMolecular GeneticsMoonNanotechnologyOrgan PreservationOtolaryngologyOutcomePatientsPharmacogenomicsPhasePhysiciansPopulationPostdoctoral FellowPreventionProcessProgram Research Project GrantsPublicationsRadiation OncologyRecordsRecruitment ActivityReproduction sporesResearchResearch PersonnelScientistScreening procedureSeedsSolidSurgical OncologyTexasToxic effectTrainingTranslational ResearchUniversitiesWomanWorkanticancer researchbasecareercareer developmentdesigndrug developmentdrug discoverygenetic epidemiologyimprovednext generationnoveloncologyprofessorprogramstherapy design
项目摘要
The goal of the Career Development Program (CDP) in head and neck cancer (HNC) is to recruit, train, and
mentor young or established scientists in basic, clinical, and translational research in HNC. The CDP is an
essential part of the overall effort of this SPORE. In order to stimulate the next generation of translational
researchers, attracting talented individuals from the level of post doctoral fellow to assistant professor and
defining research in HNC as a central theme of their career is vital. The CDP will provide financial support
and mentorship for achieving the goals stated above, while the SPORE itself will provide a nurturing and
stimulating environment for candidates who are groomed as future leaders in translational research in this
field. The faculty within the SPORE has an excellent track record in mentoring post doctoral fellows, young
scientists, and academically-oriented translational clinicians. Thus, the CDP will focus on these three types
of investigators by supporting two post doctoral fellows per year during the five-year grant period. The
Emory-Winship Cancer Drug Development and Pharmacogenomics Academy (DDPA) has already funded
two young investigators, one of whom has chosen to focus on HNC. We plan to support the recruitment of
two additional faculty physicians, including a clinical translational investigator in upper aerodigestive and
thoracic malignancies, and a basic scientist during the initial 3 years of the SPORE. The second recruitment
phase will involve the development of junior and senior faculty from multiple disciplines, potentially including
head and neck surgery and organ preservation. Support for these recruits will come from Emory University
and the Georgia Cancer Coalition, as well as the Winship Cancer Institute. These surgically oriented
investigators will be recruited and supported in the last 3 years of the SPORE. The SPORE-initiated
recruitment of new faculty will consider candidates identified through the existing recruitment process, with
special emphasis placed on seeking minority candidates and women. We have already awarded seed
packages for research to two young women from Emory's Cancer Drug Discovery Program, and the Cancer
Control Program intends to supplement this developmental program.
头颈癌(HNC)职业发展计划(CDP)的目标是招募、培训和治疗患者
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Fadlo Raja Khuri其他文献
Fadlo Raja Khuri的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Fadlo Raja Khuri', 18)}}的其他基金
Modulation of the mTOR Pathway for Lung Cancer Treatment
调节 mTOR 通路治疗肺癌
- 批准号:
8518499 - 财政年份:2012
- 资助金额:
$ 15.89万 - 项目类别:
Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy
靶向肺癌细胞信号转导以增强治疗效果
- 批准号:
7849568 - 财政年份:2006
- 资助金额:
$ 15.89万 - 项目类别:
Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy
靶向肺癌细胞信号转导以增强治疗效果
- 批准号:
8518498 - 财政年份:2006
- 资助金额:
$ 15.89万 - 项目类别:
Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy
靶向肺癌细胞信号转导以增强治疗效果
- 批准号:
7625951 - 财政年份:2006
- 资助金额:
$ 15.89万 - 项目类别:
Modulation of the mTOR Pathway for Lung Cancer Treatment
调节 mTOR 通路治疗肺癌
- 批准号:
7109527 - 财政年份:2006
- 资助金额:
$ 15.89万 - 项目类别:
Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy
靶向肺癌细胞信号转导以增强治疗效果
- 批准号:
8116326 - 财政年份:2006
- 资助金额:
$ 15.89万 - 项目类别:
Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy
靶向肺癌细胞信号转导以增强治疗效果
- 批准号:
7083450 - 财政年份:2006
- 资助金额:
$ 15.89万 - 项目类别:
Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy
靶向肺癌细胞信号转导以增强治疗效果
- 批准号:
7250877 - 财政年份:2006
- 资助金额:
$ 15.89万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 15.89万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 15.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 15.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 15.89万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 15.89万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 15.89万 - 项目类别:














{{item.name}}会员




